Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/INTERPACE BIOSCIENCES INC/ 10-Q

Quarterly Report · 10-Q

INTERPACE BIOSCIENCES INC

Quarterly Report

Filed Nov 8, 2024Accepted Nov 8, 2024, 11:05 AM ESTCIK 1054102Accession 0001493152-24-044265
View company →Permanent SEC source ↗
Share

Company context

We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management. Due to the decision of CMS to cease reimbursement coverage of our PancraGEN® test for assessing the risk of pancreatic cyst progression to cancer on April 24, 2025 which resulted in specimens for first-line fluid chemistry and PancraGEN® testing not being accepted by the Company after May 2, 2025, we are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2.

Current securities

IDXGOTC · EQUITY · Current
Historical securities (5)
IDGGWOTC · WARRANT · Historical · closed Jun 21, 2022IDXGNASDAQ · EQUITY · Historical · closed Feb 25, 2021IDXGOTC · EQUITY · Historical · closed Aug 27, 2026IDXGOTC · EQUITY · Historical · closed Aug 27, 2026IDXGDOTC · EQUITY · Historical · closed Sep 23, 2026

Recent company filings

  1. S-1/A filingOct 30, 2026
  2. FWP - filed by INTERPACE BIOSCIENCES, INC. regarding INTERPACE BIOSCIENCES, INC.Oct 15, 2026
  3. Results of Operations and Financial ConditionOct 15, 2026
  4. S-1/A filingOct 1, 2026
  5. S-1 filingSep 25, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.